VivoSim Labs appoints Tony Lialin as Chief Commercial Officer.

• VivoSim Labs appoints Tony Lialin as Chief Commercial Officer. • Lialin brings 20+ years of experience in life science platforms. • He will lead go-to-market strategy, partnerships, and expansion. • VivoSim Labs uses AI-driven analytics in 3D models for drug development. • Market opportunity in pharmaceutical and biotechnology services.

VivoSim Labs, Inc. (Nasdaq: VIVS) has appointed Tony Lialin as its Chief Commercial Officer. Lialin brings over two decades of experience in turning breakthrough life science platforms into scalable, predictable revenue. He has built commercial teams from the ground up, forged strategic pharma partnerships, and helped scale multiple businesses that were later acquired by leading industry players.

At VivoSim Labs, Lialin will lead the go-to-market strategy, partnerships, and the expansion of the company's San Diego-based services. These services combine organ-specific 3D models with AI-driven analytics to deliver decision-ready insights earlier in development. According to an internal analysis conducted by VivoSim Labs in July 2025, the global combined liver and gastrointestinal in-vitro models and toxicology services market generated $641M in revenue in 2024 [1].

The market for these services is growing rapidly, with the global in vitro liver model market growing at a 5.9% CAGR from 2020 to 2024. Biopharma sponsors are accelerating the use of non-animal new approach methodologies (NAMs), with regulatory momentum supporting validated alternatives and broader adoption of human-relevant in vitro models for ADME and toxicology [1].

VivoSim Labs applies AI to quantify multi-parametric toxicity signatures across liver and intestinal organoid assays, improving signal-to-noise in dose-response analyses. This helps project teams prioritize candidates and plan studies with greater confidence. "VivoSim Labs sits at the intersection of biology and AI. Our NAMkind™ models are designed to answer make-or-break questions earlier," said Tony Lialin, Chief Commercial Officer, VivoSim Labs [1].

"Tony has a rare track record of turning disruptive science into durable commercial engines," said Keith Murphy, Executive Chairman, VivoSim Labs. "As sponsors move rapidly to 3D, human-relevant models, they want a partner—not just a plate or a protocol—to guide critical decisions. Tony knows how to build the solutions that our customers need" [1].

References:
[1] https://finance.yahoo.com/news/vivosim-labs-appoints-tony-lialin-120500194.html